Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
Trial status:Study Complete
Trial ID:
BNT162-06
NCT ID:
EudraCT ID:
N/A
EU Trial (CTIS) Number:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Study Complete
Trial Details
This is a phase II, randomized, placebo-controlled, observer-blinded study of the safety and immunogenicity of SARS-CoV-2 messenger RNA (mRNA) vaccine (BNT162b2) in Chinese healthy population. After randomization, the trial for each participant will last for approximately 13 months. Screening period is 2 weeks prior to randomization (Day -14 to Day 0), and two doses of either SARS-CoV-2 vaccine (BNT162b2) or placebo will be given intramuscularly (IM) separated by 21 days.
Medical Condition
Trial Drug
Phase
Phase 2
Type
Interventional
Estimated Enrolment
950
Estimated Trial Date
Dec 2020 - Feb 2021
Trial Participant Requirements
Age
18 - 85 Years
Sex
Female & Male
Healthy Volunteers
Yes
Trial Locations
Location
Status
Location
Jiangsu Provincial Center for Disease Control and Prevention
Jiangsu, China, 210009
Status